201 related articles for article (PubMed ID: 23381396)
1. Dynamics of cellular immune responses in the acute phase of dengue virus infection.
Yoshida T; Omatsu T; Saito A; Katakai Y; Iwasaki Y; Kurosawa T; Hamano M; Higashino A; Nakamura S; Takasaki T; Yasutomi Y; Kurane I; Akari H
Arch Virol; 2013 Jun; 158(6):1209-20. PubMed ID: 23381396
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.
Grifoni A; Angelo M; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Botten J; Boyson J; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148797
[TBL] [Abstract][Full Text] [Related]
3. Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model.
Amorim JH; dos Santos Alves RP; Bizerra R; Araújo Pereira S; Ramos Pereira L; Nascimento Fabris DL; Santos RA; Romano CM; de Souza Ferreira LC
Virology; 2016 Jan; 487():41-9. PubMed ID: 26496698
[TBL] [Abstract][Full Text] [Related]
4. Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques.
Mladinich KM; Piaskowski SM; Rudersdorf R; Eernisse CM; Weisgrau KL; Martins MA; Furlott JR; Partidos CD; Brewoo JN; Osorio JE; Wilson NA; Rakasz EG; Watkins DI
Immunogenetics; 2012 Feb; 64(2):111-21. PubMed ID: 21881953
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
[TBL] [Abstract][Full Text] [Related]
6. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
Moi ML; Takasaki T; Saijo M; Kurane I
Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
[TBL] [Abstract][Full Text] [Related]
7. Human immune responses to dengue viruses.
Kurane I; Innis BL; Nimmannitya S; Nisalak A; Rothman AL; Livingston PG; Janus J; Ennis FA
Southeast Asian J Trop Med Public Health; 1990 Dec; 21(4):658-62. PubMed ID: 1983049
[TBL] [Abstract][Full Text] [Related]
8. Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance.
Ng KH; Zhang SL; Tan HC; Kwek SS; Sessions OM; Chan CY; Liu ID; Lee CK; Tambyah PA; Ooi EE; Yap HK
Cell Host Microbe; 2019 Nov; 26(5):601-605.e3. PubMed ID: 31676304
[TBL] [Abstract][Full Text] [Related]
9. Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.
Moi ML; Ami Y; Shirai K; Lim CK; Suzaki Y; Saito Y; Kitaura K; Saijo M; Suzuki R; Kurane I; Takasaki T
Am J Trop Med Hyg; 2015 Feb; 92(2):370-6. PubMed ID: 25548383
[TBL] [Abstract][Full Text] [Related]
10. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
[TBL] [Abstract][Full Text] [Related]
11. T lymphocyte responses to heterologous secondary dengue virus infections.
Rothman AL
Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E36-41. PubMed ID: 19751400
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans.
Moi ML; Takasaki T; Omatsu T; Nakamura S; Katakai Y; Ami Y; Suzaki Y; Saijo M; Akari H; Kurane I
J Gen Virol; 2014 Mar; 95(Pt 3):591-600. PubMed ID: 24323638
[TBL] [Abstract][Full Text] [Related]
13. The Role of Heterotypic DENV-specific CD8
Talarico LB; Batalle JP; Byrne AB; Brahamian JM; Ferretti A; García AG; Mauri A; Simonetto C; Hijano DR; Lawrence A; Acosta PL; Caballero MT; Paredes Rojas Y; Ibañez LI; Melendi GA; Rey FA; Damonte EB; Harris E; Polack FP
EBioMedicine; 2017 Jun; 20():202-216. PubMed ID: 28483582
[TBL] [Abstract][Full Text] [Related]
14. T helper type 2 bias and type 17 suppression in primary dengue virus infection in infants and young children.
Talarico LB; Bugna J; Wimmenauer V; Espinoza MA; Quipildor MO; Hijano DR; Beccaria M; Wurster V; Cavagnaro LE; Martinez D; Fattore G; Batalle JP; Acosta PL; Reynoso N; Melendi GA; Rey FA; Libster R; Polack FP
Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):411-9. PubMed ID: 23764739
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner.
Beaumier CM; Mathew A; Bashyam HS; Rothman AL
J Infect Dis; 2008 Feb; 197(4):608-17. PubMed ID: 18275279
[TBL] [Abstract][Full Text] [Related]
16. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
[TBL] [Abstract][Full Text] [Related]
17. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.
Ito M; Katakai Y; Ono F; Akari H; Mukai RZ; Takasaki T; Kotaki A; Kurane I
Arch Virol; 2011 Jun; 156(6):1073-7. PubMed ID: 21409446
[TBL] [Abstract][Full Text] [Related]
18. A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice.
Hunsawong T; Sunintaboon P; Warit S; Thaisomboonsuk B; Jarman RG; Yoon IK; Ubol S; Fernandez S
Vaccine; 2015 Mar; 33(14):1702-10. PubMed ID: 25701315
[TBL] [Abstract][Full Text] [Related]
19. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
20. Immunopathological mechanisms in dengue and dengue hemorrhagic fever.
Green S; Rothman A
Curr Opin Infect Dis; 2006 Oct; 19(5):429-36. PubMed ID: 16940865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
